Lv53
1398 积分 2024-04-22 加入
Sovleplenib (HMPL-523), a novel Syk inhibitor, for patients with primary immune thrombocytopenia in China: a randomised, double-blind, placebo-controlled, phase 1b/2 study
2天前
已完结
Targeted protein degradation for cancer therapy
11天前
已完结
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
14天前
已完结
Anti–PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation
24天前
已完结
Dual Inhibition of SYK and EGFR Overcomes Chemoresistance by Inhibiting CDC6 and Blocking DNA Replication
24天前
已完结
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies
24天前
已完结
Regulatory interplay between Vav1, Syk and β-catenin occurs in lung cancer cells
24天前
已完结
Methods for Recombinant Production and Purification of Peptides as SUMO‐Peptide‐Intein Fusion Proteins to Protect from Degradation
25天前
已完结
Simple and rapid pipeline for the production of cyclic and linear small-sized peptides in E. coli
25天前
已关闭
The SYK tyrosine kinase: a crucial player in diverse biological functions
1个月前
已完结
皖公网安备34019202002308
